Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery

Journal of Controlled Release

Volumn 241, Issue , 2016, Pages 174-185

  Ingato, Dominique ^a   Lee, Jong Uk ^b   Sim, Sang Jun ^b   Kwon, Young Jik ^a,b,c  

^a University of California at Irvine   (United States)

^b Korea University   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Exosomes; Extracellular vesicles; Microvesicles; Therapeutic delivery

Indexed keywords

CONTROLLED DRUG DELIVERY;

CURRENT THEORIES; EXOSOMES; EXTRACELLULAR; IDENTIFYING METHODS; MASS PRODUCTION; MICROVESICLES; REPRODUCIBILITIES; THERAPEUTIC DELIVERY;

BIOMEDICAL ENGINEERING;

CALCIUM; DRUG CARRIER; NANOPARTICLE; PROTEIN; DRUG;

ANTIBODY AFFINITY; CALCIUM CELL LEVEL; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; EXOSOME; FLOW CYTOMETRY; GENE TARGETING; MEMBRANE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SURFACE PLASMON RESONANCE; CHEMISTRY; GENE TRANSFER; HUMAN; PARTICLE SIZE; PHYSIOLOGY; PROCEDURES; SURFACE PROPERTY;

DRUG DELIVERY SYSTEMS; EXTRACELLULAR VESICLES; GENE TRANSFER TECHNIQUES; HUMANS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SURFACE PROPERTIES;

EID: 84989172766     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.09.016     Document Type: Review

References (141)

1. [1] Ganta, S., Devalapally, H., Shahiwala, A., Amiji, M., A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 126:3 (2008), 187–204, 10.1016/j.jconrel.2007.12.017.
2. [2] Hillaireau, H., Couvreur, P., Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66:17 (2009), 2873–2896, 10.1007/s00018-009-0053-z.
3. [3] Kesharwani, P., Gajbhiye, V., Jain, N.K., A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33:29 (2012), 7138–7150, 10.1016/j.biomaterials.2012.06.068.
4. [4] Petros, R.A., JM, D.S., Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9:8 (2010), 615–627, 10.1038/nrd2591.
5. [5] Allen, T.M., Cullis, P.R., Drug delivery systems: entering the mainstream. Science 303:5665 (2004), 1818–1822, 10.1126/science.1095833.
6. [6] El-Aneed, A., An overview of current delivery systems in cancer gene therapy. J. Control. Release 94:1 (2004), 1–14, 10.1016/j.jconrel.2003.09.013.
7. [7] Giacca, M., Zacchigna, S., Virus-mediated gene delivery for human gene therapy. J. Control. Release 161:2 (2012), 377–388, 10.1016/j.jconrel.2012.04.008.
8. [8] Brown, M.D., Schätzlein, A.G., Uchegbu, I.F., Gene delivery with synthetic (nonviral) carriers. Int. J. Pharm. 229:1–2 (2001), 1–21, 10.1016/S0378-5173(01)00861-4.
9. [9] Nakanishi, W., Minami, K., Kumar, L., Ji, Q., Hill, J.P., Ariga, K., ScienceDirect bioactive nanocarbon assemblies: nanoarchitectonics and applications. Nano Today 9:3 (2014), 378–394, 10.1016/j.nantod.2014.05.002.
10. [10] Yang, D., Ma, P., Hou, Z., Cheng, Z., Li, C., Lin, J., Current advances in lanthanide ion (Ln3 +)-based upconversion nanomaterials for drug delivery. Royal Society of Chemistry, 2015, 10.1039/C4CS00155A.
11. [11] Ariga, K., Kawakami, K., Ebara, M., Kotsuchibashi, Y., Ji, Q., Hill, J.P., Bioinspired nanoarchitectonics as emerging drug delivery systems. New J. Chem. 38:11 (2014), 5149–5163, 10.1039/C4NJ00864B.
12. [12] Daraee, H., Etemadi, A., Kouhi, M., et al. Application of liposomes in medicine and drug delivery. Artif Cells, Nanomedicine, Biotechnol. 44:1 (2016), 381–391, 10.3109/21691401.2014.953633.
13. [13] Bunker, A., Magarkar, A., Viitala, T., Rational design of liposomal drug delivery systems, a review: combined experimental and computational studies of lipidmembranes, liposomes and their PEGylation. Biochim. Biophys. Acta 2016 (1858), 2334–2352, 10.1016/j.bbamem.2016.02.025.
14. [14] Thomas, C.E., Ehrhardt, A., Kay, M.A., Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4:5 (2003), 346–358, 10.1038/nrg1066.
15. [15] Lv, H., Zhang, S., Wang, B., Cui, S., Yan, J., Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114:1 (2006), 100–109, 10.1016/j.jconrel.2006.04.014.
16. [16] Suk, J.S., Xu, Q., Kim, N., Hanes, J., Ensign, L.M., PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99 (2016), 28–51, 10.1016/j.addr.2015.09.012.
17. [17] Silva, A.K.A., Di Corato, R., Pellegrino, T., et al. Cell-derived vesicles as a bioplatform for the encapsulation of theranostic nanomaterials. Nanoscale 5:23 (2013), 11374–11384, 10.1039/c3nr01541f.
18. [18] Vader, P., Mol, E.A., Pasterkamp, G., Schiffelers, R.M., Extracellular vesicles for drug delivery. Adv. Drug Deliv. Rev., 2016, 10.1016/j.addr.2016.02.006 In Press.
19. [19] Tominaga, N., Yoshioka, Y., Ochiya, T., A novel platform for cancer therapy using extracellular vesicles. Adv. Drug Deliv. Rev. 95 (2015), 50–55, 10.1016/j.addr.2015.10.002.
20. [20] Zhang, B., Wee, R., Yeo, Y., Tan, K.H., SK, L., Focus on Extracellular Vesicles: Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles. 2016, 10.3390/ijms17020174.
21. [21] Théry, C., Zitvogel, L., Amigorena, S., Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2:8 (2002), 569–579, 10.1038/nri855.
22. [22] Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9:6 (2007), 654–659, 10.1038/ncb1596.
23. [23] Tian, Y., Li, S., Song, J., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35:7 (2014), 2383–2390, 10.1016/j.biomaterials.2013.11.083.
24. [24] Lamichhane, T.N., Sokic, S., Schardt, J.S., Raiker, R.S., Lin, J.W., Jay, S.M., Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine. Tissue Eng Part B Rev. 21:1 (2015), 45–54, 10.1089/ten.teb.2014.0300.
25. [25] Tan, S., Wu, T., Zhang, D., Zhang, Z., Cell or cell membrane-based drug delivery systems. Theranostics. 5:8 (2015), 863–881, 10.7150/thno.11852.
26. [26] Sezgin, E., Kaiser, H.-J., Baumgart, T., Schwille, P., Simons, K., Levental, I., Elucidating membrane structure and protein behavior using giant plasma membrane vesicles. Nat. Protoc. 7:6 (2012), 1042–1051, 10.1038/nprot.2012.059.
27. [27] Zeng, F., Yang, W., Huang, J., Chen, Y., Chen, Y., Determination of the lowest concentrations of aldehyde fixatives for completely fixing various cellular structures by real-time imaging and quantification. Histochem. Cell Biol. 139:5 (2013), 735–749, 10.1007/s00418-012-1058-5.
28. [28] Sun, D., Zhuang, X., Xiang, X., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 18:9 (2010), 1606–1614, 10.1038/mt.2010.105.
29. [29] Pascucci, L., Coccè, V., Bonomi, A., et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release 192 (2014), 262–270, 10.1016/j.jconrel.2014.07.042.
30. [30] Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., Wood, M.J.A., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29:4 (2011), 341–345, 10.1038/nbt.1807.
31. [31] Katsuda, T., Kosaka, N., Takeshita, F., Ochiya, T., The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics 13:10–11 (2013), 1637–1653, 10.1002/pmic.201200373.
32. [32] Smith, J.A., Ng, K.S., Mead, B.E., et al. Extracellular vesicles: commercial potential as byproducts of cell manufacturing for research and therapeutic use. Bioprocess Int. 13:4 (2015), 1–13.
33. [33] Fuhrmann, G., Herrmann, I.K., Stevens, M.M., Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10:3 (2015), 397–409, 10.1016/j.nantod.2015.04.004.
34. [34] Vlassov, A.V., Magdaleno, S., Setterquist, R., Conrad, R., Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta, Gen. Subj. 1820:7 (2012), 940–948, 10.1016/j.bbagen.2012.03.017.
35. [35] Whitford, W., Ludlow, J.W., Cadwell, J.J.S., Continuous production of exosomes. Genet. Eng. Biotechnol. News, 35, 2015, 16.
36. [36] EL Andaloussi, S., Mäger, I., Breakefield, X.O., Wood, M.J.A., Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12:5 (2013), 347–357, 10.1038/nrd3978.
37. [37] van Dommelen, S.M., Vader, P., Lakhal, S., et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J. Control. Release 161:2 (2012), 635–644, 10.1016/j.jconrel.2011.11.021.
38. [38] Braicu, C., Tomuleasa, C., Monroig, P., Cucuianu, A., Berindan-Neagoe, I., Calin, G.A., Exosomes as divine messengers: are they the Hermes of modern molecular oncology?. Cell Death Differ. 22:1 (2015), 34–45, 10.1038/cdd.2014.130.
39. [39] György, B., Szabó, T.G., Pásztói, M., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 68:16 (2011), 2667–2688, 10.1007/s00018-011-0689-3.
40. [40] J. Simpson, R., S., M., Extracellular microvesicles: the need for internationally recognised nomenclature and stringent purification criteria. J. Proteomics Bioinform., 5(2), 2012, 10000, 10.4172/jpb.10000e10.
41. [41] Février, B., Raposo, G., Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16:4 (2004), 415–421, 10.1016/j.ceb.2004.06.003.
42. [42] Gesierich, S., Berezovskiy, I., Ryschich, E., Zo, M., Systemic induction of the angiogenesis switch by the tetraspanin D6/CO-029. Cancer Res. 66:14 (2006), 7083–7095, 10.1158/0008-5472.CAN-06-0391.
43. [43] Riteau, B., Faure, F., Menier, C., et al. Exosomes bearing HLA-G are released by melanoma cells. Hum. Immunol. 64:11 (2003), 1064–1072, 10.1016/j.humimm.2003.08.344.
44. [44] Dolo, V., Li, R., Dillinger, M., et al. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim. Biophys. Acta 1486:2–3 (2000), 265–274 http://www.ncbi.nlm.nih.gov/pubmed/10903477.
45. [45] Akers, J.C., Gonda, D., Kim, R., Carter, B.S., Chen, C.C., Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neuro-Oncol. 113:1 (2013), 1–11, 10.1007/s11060-013-1084-8.
46. [46] Szajnik, M., Czystowska, M., Szczepanski, M.J., Mandapathil, M., Whiteside, T.L., Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One, 5(7), 2010, e11469, 10.1371/journal.pone.0011469.
47. [47] Kim, S.H., Lechman, E.R., Bianco, N., et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol. 174:10 (2005), 6440–6448, 10.4049/jimmunol.174.10.6440.
48. [48] Gatti, S., Bruno, S., Deregibus, M.C., et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 26:5 (2011), 1474–1483, 10.1093/ndt/gfr015.
49. [49] Cantaluppi, V., Gatti, S., Medica, D., et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia–reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int. 82:4 (2012), 412–427, 10.1038/ki.2012.105.
50. [50] Cai, Z., Yang, F., Yu, L., et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J. Immunol. 188:12 (2012), 5954–5961, 10.4049/jimmunol.1103466.
51. [51] Bruno, S., Grange, C., Collino, F., et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One, 7(3), 2012, e33115, 10.1371/journal.pone.0033115.
52. [52] Ratajczak, J., Miekus, K., Kucia, M., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20:5 (2006), 847–856, 10.1038/sj.leu.2404132.
53. [53] Camussi, G., Deregibus, M., Bruno, S., Grange, C., Fonsato, V., Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 1:1 (2011), 98–110.
54. [54] Wahlgren, J., Karlson, T.D.L., Brisslert, M., et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res., 40(17), 2012, e130, 10.1093/nar/gks463.
55. [55] Baj-Krzyworzeka, M., Szatanek, R., Weglarczyk, K., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol. Immunother. 55:7 (2006), 808–818, 10.1007/s00262-005-0075-9.
56. [56] Liu, C., Yu, S., Zinn, K., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176:3 (2006), 1375–1385, 10.4049/jimmunol.176.3.1375.
57. [57] Fairchild, P.J., Immunological Tolerance: Methods and Protocols. 2007, Humana Press Inc., Totowa, NJ.
58. [58] Hedlund, M., Nagaeva, O., Kargl, D., Baranov, V., Mincheva-Nilsson, L., Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One, 6(2), 2011, e16899, 10.1371/journal.pone.0016899.
59. [59] Skokos, D., Botros, H.G., Demeure, C., et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo 1. J. Immunol. 170 (2003), 3037–3045, 10.4049/jimmunol.170.6.3037.
60. [60] Théry, C., Clayton, A., Amigorena, S., Raposo, G., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current Protocols in Cell Biology, 2006, 3.22.1–3.22.29.
61. [61] Witwer, K.W., Buza, E.I., Bernis, L.T., et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell Vesicles. 2:20360 (2013), 1–25.
62. [62] Tauro, B.J., Greening, D.W., Mathias, R.A., et al. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 56 (2012), 293–304, 10.1016/j.ymeth.2012.01.002.
63. [63] Momen-heravi, F., Balaj, L., Alian, S., et al. Current methods for the isolation of extracellular vesicles. Biol. Chem. 394:10 (2013), 1253–1262, 10.1515/hsz-2013-0141.
64. [64] Lamparski, H.G., Metha-damani, A., Yao, J., et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Imm. 270 (2002), 211–226.
65. [65] Bobri, A., Colombo, M., Krumeich, S., Raposo, G., Thery, C., Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation., 1(18397), 2012, 1–11.
66. [66] Alvarez, M.L., Khosroheidari, M., Ravi, R.K., Distefano, J.K., Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 82 (2012), 1024–1032, 10.1038/ki.2012.256.
67. [67] Zhang, Z., Wang, C., Li, T., Zhe, L., Li, L., Comparison of ultracentrifugation and density gradient separation methods for isolating Tca8113 human tongue cancer cell line-derived exosomes. Oncol. Lett. 8 (2014), 1701–1706, 10.3892/ol.2014.2373.
68. [68] Simpson, R.J., Lim, J.W.E., Moritz, R.L., Mathivanan, S., Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics. 6:3 (2009), 267–283.
69. [69] Kanwar, S.S., Dunlay, C.J., Simeone, D.M., Nagrath, S., Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip 14 (2014), 1891–1900, 10.1039/c4lc00136b.
70. [70] Wubbolts, R., Leckie, R.S., Veenhuizen, P.T.M., et al. Proteomic and biochemical analyses of human B cell-derived exosomes. J. Biol. Chem. 278:13 (2003), 10963–10972, 10.1074/jbc.M207550200.
71. [71] Clayton, A., Court, J., Navabi, H., et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J. Immunol. Methods 247 (2001), 163–174.
72. [72] Chen, C., Skog, J., Hsu, C.-H., et al. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 10:4 (2010), 505–511, 10.1039/b916199f.
73. [73] He, M., Crow, J., Roth, M., Godwin, A.K., Lab on a chip integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip 14 (2014), 3773–3780, 10.1039/C4LC00662C.
74. [74] Davies, R.T., Kim, J., Jang, C., Choi, E., Gho, S., Park, J., Lab on a chip microfluidic filtration system to isolate extracellular vesicles from blood. Lab Chip 12 (2012), 5202–5210, 10.1039/c2lc41006k.
75. [75] Voldman, J., Electrical forces for microscale cell manipulation. Annu. Rev. Biomed. Eng. 8 (2006), 425–454, 10.1146/annurev.bioeng.8.061505.095739.
76. [76] Liu, Z.W., Wu, H., Fine, D., et al. Ciliated micropillars for the microfluidic-based isolation of nanoscale lipid vesicles. Lab Chip 13 (2013), 2879–2882, 10.1039/c3lc41343h.
77. [77] Lee, K., Shao, H., Weissleder, R., Lee, H., Acoustic purification of extracellular microvesicles. ACS Nano 9:3 (2015), 2321–2327.
78. [78] Kadiu, I., Narayanasamy, P., Dash, P.K., Zhang, W., Gendelman, H.E., Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J. Immunol. 189 (2016), 744–754, 10.4049/jimmunol.1102244.
79. [79] Enderle, D., Spiel, A., Coticchia, C.M., et al. Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column-based method. PLoS One, 2015, 1–19, 10.1371/journal.pone.0136133.
80. [80] Gardiner, C., Ferreira, Y.J., Dragovic, R.A., Redman, C.W.G., Sargent, I.L., Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. J. Extracell Vesicles. 2:19671 (2013), 1–11.
81. [81] Kastelowitz, N., Yin, H., Exosomes and microvesicles: identification and targeting by particle size and lipid chemical probes. Chembiochem 15 (2014), 923–928, 10.1002/cbic.201400043.
82. [82] Soo, C.Y., Song, Y., EC, C., AC, R., Gunn-, F., SJ, P., Nanoparticle tracking analysis monitors microvesicle and exosome secretion from immune cells. Immunology 136 (2012), 192–197, 10.1111/j.1365-2567.2012.03569.x.
83. [83] Dragovic, R.A., Gardiner, C., Brooks, A.S., et al. Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine Nanotechnology, Biol. Med. 7:6 (2011), 780–788, 10.1016/j.nano.2011.04.003.
84. [84] Robert, S., Lacroix, R., Poncelet, P., et al. High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles — brief report. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 1054–1058, 10.1161/ATVBAHA.111.244616.
85. [85] van der Pol, E., Hoekstra, A.G., Sturk, A., Otto, C., van Leeuwen, T.G., Nieuwland, R., Optical and non-optical methods for detection and characterization of microparticles and exosomes. J. Thromb. Haemost. 8 (2010), 2596–2607, 10.1111/j.1538-7836.2010.04074.x.
86. [86] Rupert, L.M., La, C., Eldh, M., et al. Determination of exosome concentration in solution using surface plasmon resonance spectroscopy. Anal. Chem. 86 (2014), 5929–5936.
87. [87] Im, H., Shao, H., Park, Y.I.I., et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat. Biotechnol. 32:5 (2014), 490–495, 10.1038/nbt.2886.
88. [88] Turiák, L., Misják, P., Szabó, T.G., et al. Proteomic characterization of thymocyte-derived microvesicles and apoptotic bodies in BALB/c mice. J. Proteome 74:10 (2011), 2025–2033, 10.1016/j.jprot.2011.05.023.
89. [89] Conde-vancells, J., Rodriguez-suarez, E., Embade, N., et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J. Proteome 7 (2008), 5157–5166.
90. [90] Llorente, A., Skotland, T., Sylvänne, T., et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim. Biophys. Acta 2013 (1831), 1302–1309, 10.1016/j.bbalip.2013.04.011.
91. [91] Abels, E.R., Breakefield, X.O., Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell. Mol. Neurobiol. 36:3 (2016), 301–312, 10.1007/s10571-016-0366-z.
92. [92] Zaborowski, M.P., Balaj, L., Breakefield, X.O., Lai, C.P., Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience 65:8 (2015), 783–797, 10.1093/biosci/biv084.
93. [93] Rupert, D.L.M., Claudio, V., Lässer, C., Bally, M., Methods for the physical characterization and quantification of extracellular vesicles in biological samples. Biochim. Biophys. Acta, 2016, 10.1016/j.bbagen.2016.07.028 In Press.
94. [94] Lee, Y., El Andaloussi, S., Wood, M.J.A., Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum. Mol. Genet. 21:R1 (2012), R125–R134, 10.1093/hmg/dds317.
95. [95] Skog J, Wurdinger T, Rijn S Van, et al. Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008;10(12):1470–1476. doi: http://dx.doi.org/10.1038/ncb1800.Glioblastoma.
96. [96] Chaput, N., Taieb, J., Schartz, N.E.C., Andre, F., Angevin, E., Zitvogel, L., Exosome-based immunotherapy. Cancer Immunol. Immunother. 53:3 (2004), 234–239, 10.1007/s00262-003-0472-x.
97. [97] Albanese, J., Meterissian, S., Kontogiannea, M., et al. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 91:10 (1998), 3862–3874 http://www.ncbi.nlm.nih.gov/pubmed/9573024.
98. [98] Obregon, C., Rothen-Rutishauser, B., Gitahi, S.K., Gehr, P., Nicod, L.P., Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens. Am. J. Pathol. 169:6 (2006), 2127–2136, 10.2353/ajpath.2006.060453.
99. [99] Théry, C., Ostrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9:8 (2009), 581–593, 10.1038/nri2567.
100. [100] Chaput, N., Théry, C., Exosomes: immune properties and potential clinical implementations. Semin. Immunopathol. 33:5 (2011), 419–440, 10.1007/s00281-010-0233-9.
101. [101] Savina, A., Furlan, M., Vidal, M., Colombo, M.I., Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J. Biol. Chem. 278:22 (2003), 20083–20090, 10.1074/jbc.M301642200.
102. [102] Distler, J.H.W., Pisetsky, D.S., Huber, L.C., Kalden, J.R., Gay, S., Distler, O., Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum. 52:11 (2005), 3337–3348, 10.1002/art.21350.
103. [103] Fauré, J., Lachenal, G., Court, M., et al. Exosomes are released by cultured cortical neurones. Mol. Cell. Neurosci. 31:4 (2006), 642–648, 10.1016/j.mcn.2005.12.003.
104. [104] Krämer-Albers, E.-M., Bretz, N., Tenzer, S., et al. Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: trophic support for axons?. Proteomics Clin. Appl. 1:11 (2007), 1446–1461, 10.1002/prca.200700522.
105. [105] Miyoshi, H., Umeshita, K., Sakon, M., et al. Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury. Gastroenterology 110:6 (1996), 1897–1904, 10.1053/gast.1996.v110.pm8964416.
106. [106] King, H.W., Michael, M.Z., Gleadle, J.M., Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer, 12(1), 2012, 421, 10.1186/1471-2407-12-421.
107. [107] Wysoczynski, M., Ratajczak, M.Z., Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int. J. Cancer 125:7 (2009), 1595–1603, 10.1002/ijc.24479.
108. [108] Parolini, I., Federici, C., Raggi, C., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284:49 (2009), 34211–34222, 10.1074/jbc.M109.041152.
109. [109] de Jong, O.G., Verhaar, M.C., Chen, Y., et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. J. Extracell Vesicles. 1 (2012), 1–12, 10.3402/jev.v1i0.18396.
110. [110] Scott, R.E., Perkins, R.G., Zschunke, M.A., BJ, H., PB, M., Plasma membrane vesiculation in 3T3 and SV3T3 cells. I. Morphological and biochemical characterization. J. Cell Sci. 35 (1979), 229–243.
111. [111] Scott, R.E., Plasma membrane vesiculation: a new technique for isolation of plasma membranes. Science 194:4266 (1976), 743–745, 10.1126/science.982044.
112. [112] Dalle-Donne, I., Rossi, R., Milzani, A., Di Simplicio, P., Colombo, R., The actin cytoskeleton response to oxidants: from small heat shock protein phosphorylation to changes in the redox state of actin itself. Free Radic. Biol. Med. 31:12 (2001), 1624–1632.
113. [113] Charras, G.T., Hu, C.-K., Coughlin, M., Mitchison, T.J., Reassembly of contractile actin cortex in cell blebs. J. Cell Biol. 175:3 (2006), 477–490, 10.1083/jcb.200602085.
114. [114] Rafelski, S.M., Theriot, J.A., Crawling toward a unified model of cell motility: spatial and temporal regulation of actin dynamics. Annu. Rev. Biochem. 73:1 (2004), 209–239, 10.1146/annurev.biochem.73.011303.073844.
115. [115] Hagmann, J., Burger, M.M., Dagan, D., Regulation of plasma membrane blebbing by the cytoskeleton. J. Cell. Biochem. 73:4 (1999), 488–499 10.1002/(SICI)1097-4644(19990615)73:4 < 488::AID-JCB7 > 3.0.CO;2-P.
116. [116] Kosaka, N., Iguchi, H., Yoshioka, Y., et al. Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells. 285 (23), 2010, 17442–17452, 10.1074/jbc.M110.107821.
117. [117] Akao, Y., Iio, A., Itoh, T., et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol. Ther. 19:2 (2011), 395–399, 10.1038/mt.2010.254.
118. [118] Saari, H., Lázaro-ibáñez, E., Viitala, T., Vuorimaa-laukkanen, E., Siljander, P., Yliperttula, M., Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells. J. Control. Release 220 (2015), 727–737, 10.1016/j.jconrel.2015.09.031.
119. [119] Hood, J.L., Scott, M.J., Wickline, S.A., Maximizing exosome colloidal stability following electroporation. Anal. Biochem. 448 (2014), 41–49, 10.1016/j.ab.2013.12.001.
120. [120] Haney, M.J., Klyachko, N.L., Zhao, Y., et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control. Release 207 (2015), 18–30, 10.1016/j.jconrel.2015.03.033.
121. [121] Munoz, J.L., Bliss, S.A., SJ, G., SH, R., KL, L., P., R., Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids, 2, 2013, e126, 10.1038/mtna.2013.60 April.
122. [122] Ohno, S., Takanashi, M., Sudo, K., et al. Systemically injected exosomes targeted to EGFR deliver antitumor MicroRNA to breast cancer cells. Mol. Ther. 21:1 (2012), 185–191, 10.1038/mt.2012.180.
123. [123] Alhasan, A.H., Patel, P.C., Choi, C.H.J., Mirkin, C.A., Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents. Small 10:1 (2014), 186–192, 10.1002/smll.201302143.
124. [124] Fuhrmann, G., Serio, A., Mazo, M., Nair, R., Stevens, M.M., Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J. Control. Release 205 (2014), 35–44, 10.1016/j.jconrel.2014.11.029.
125. [125] Hung, M.E., Leonard, J.N., Stabilization of exosome targeting peptides via engineered glycosylation. J. Biol. Chem. 290 (2015), 8166–8172, 10.1074/jbc.M114.621383.
126. [126] Wang, E., Ascierto, P.A., Stroncek, D.F., Developments in T Cell Based Cancer Immunotherapies. 2015.
127. [127] Kooijmans, S.A.A., Go, C., Roffler, S.R., Solinge, W.W.V., Vader, P., Schiffelers, R.M., Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J. Extracell Vesicles. 5 (2016), 1–11.
128. [128] Pegtel, D.M., Cosmopoulos, K., Thorley-Lawson, D.A., et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U. S. A. 107:14 (2010), 6328–6333, 10.1073/pnas.0914843107.
129. [129] Liu, Y., Li, D., Liu, Z., et al. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci. Rep., 5(November), 2015, 17543, 10.1038/srep17543.
130. [130] Momen-Heravi, F., Bala, S., Bukong, T., Szabo, G., Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine Nanotechnology, Biol. Med. 10:7 (2014), 1517–1527, 10.1016/j.nano.2014.03.014.
131. [131] Hung, M.E., Leonard, J.N., A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J. Extracell Vesicles. 5:31027 (2016), 1–13, 10.3402/jev.v5.31027.
132. [132] Shimoda, A., Ueda, K., Nishiumi, S., et al. Exosomes as nanocarriers for systemic delivery of the helicobacter pylori virulence factor CagA. Sci. Rep., 6, 2016, 18346, 10.1038/srep18346.
133. [133] Aspe, J.R., Osterman, C.J.D., Jutzy, J.M.S., Deshields, S., Whang, S., Wall, N.R., Enhancement of Gemcitabine Sensitivity in Pancreatic Adenocarcinoma by Novel Exosome-Mediated Delivery of the Survivin-T34 A Mutant. 1, 2014, 1–9.
134. [134] Jang, S.C., Kim, O.Y., CM, Y., et al. Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors. 9, 2013, 7698–7710.
135. [135] Munagala, R., Aqil, F., Jeyabalan, J., Gupta, R.C., Bovine milk-derived exosomes for drug delivery. Cancer Lett. 371:1 (2016), 48–61, 10.1016/j.canlet.2015.10.020.
136. [136] Bartolini, E., Ianni, E., Frigimelica, E., et al. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. J. Extracell Vesicles. 2:20181 (2013), 1–14.
137. [137] Cheng, Y., Schorey, J.S., Exosomes carrying mycobacterial antigens can protect mice against an M. tuberculosis infection. Eur. J. Immunol. 43:12 (2013), 3279–3290, 10.1097/MPG.0b013e3181a15ae8.Screening.
138. [138] Mahaweni, N.M., Kaijen-Lambers, M.E.H., Dekkers, J., Aerts, J.G.J.V., Hegmans, J.P.J.J., Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell vesicles. 2 (2013), 1–6, 10.3402/jev.v2i0.22492.
139. [139] Viaud, S., Thery, C., Ploix, S., et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res. 70:4 (2010), 1281–1285, 10.1158/0008-5472.CAN-09-3276.
140. [140] Colino, J., Snapper, C.M., Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen. J. Immunol. 177:6 (2006), 3757–3762, 10.4049/jimmunol.177.6.3757.
141. [141] del Cacho, E., Gallego, M., Lee, S.H., et al. Induction of protective immunity against Eimeria tenella infection using antigen-loaded dendritic cells (DC) and DC-derived exosomes. Vaccine 29:21 (2011), 3818–3825, 10.1016/j.vaccine.2011.03.022.